The COVID-19 Long Haul Foundation

Treatment, Referral & Educational Support for COVID-19 Illnesses & Vaccine Injury

by: John MurphyPosted on:

Long-COVID: assessment of circulating markers suggests no cerebral neuronal damage, neuroinflammation or systemic inflammation–a controlled study

Roald Omdal, Ole Bernt Lenning, Grete Jonsson, Scientific Reports , Article number:  (2026) Cite this article

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Abstract

Long-COVID remains incompletely understood, particularly regarding the roles of peripheral systemic inflammation and neuroinflammation. The persistence and extent of these processes remain debated. We conducted a single-center, age- and sex-matched case–control study at Stavanger University Hospital, Norway, recruiting participants from the general population. Forty-eight long-COVID patients and 48 recovered controls were included at a median of 69 weeks post-SARS-CoV-2 infection. Exclusion criteria included autoimmune or chronic inflammatory diseases, cancer, and other conditions affecting fatigue. Plasma levels of neurofilament light (NfL), glial fibrillary acidic protein (GFAP), triggering receptor expressed on myeloid cells 2 (TREM2), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were measured using ultrasensitive NULISA™ technology. CRP, TNF-α, and IL-6 were additionally assessed by a standard hospital laboratory method (CRP) and MSD S-Plex chemiluminescence immunoassay (TNF-α and IL-6 MSD). No significant differences in NfL or GFAP were observed between groups, suggesting no ongoing neuronal injury or neuroinflammation. Routine immunoassays showed no differences for inflammatory markers. In unadjusted analyses using ultrasensitive assays, long-COVID patients showed nominally elevated levels of CRP (p = 0.04), TNF-α (p  = 0.01), IL-6 (p = 0.02), and TREM2 (p =  0.02). However, these differences did not survive correction for multiple comparisons (all false discovery rate-adjusted p > 0.05). The absence of neuroinflammation markers is consistent with the hypothesis that persistent long-COVID symptoms are unlikely due to ongoing neuronal injury or central nervous system inflammation. Alternatively, persisting long-COVID symptoms may reflect a chronic, extremely low-level immune activation, that contributes to fatigue, pain, and other sickness phenomena through mechanisms such as pro-inflammatory signaling in the brain, or epigenetic mechanisms underlying the sickness behavior response. These findings should be considered preliminary and warrant validation in larger, longitudinal cohorts.

References

  1. Al-Aly, Z. et al. Long COVID science, research and policy. Nat Med. 30(8), 2148–2164 (2024).Google Scholar 
  2. Shen, Q. et al. COVID-19 illness severity and 2-year prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and Denmark. Lancet Reg Health Eur. 35, 100756 (2023).Google Scholar 
  3. Tran, V. T., Porcher, R., Pane, I. & Ravaud, P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 13(1), 1812 (2022).Google Scholar 
  4. Mizrahi, B. et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 380, e072529 (2023).Google Scholar 
  5. Umesh, A., Pranay, K., Pandey, R. C. & Gupta, M. K. Evidence mapping and review of long-COVID and its underlying pathophysiological mechanism. Infection 50(5), 1053–1066 (2022).Google Scholar 
  6. Lai, Y. J. et al. Biomarkers in long COVID-19: A systematic review. Front Med (Lausanne). 10, 1085988 (2023).Google Scholar 
  7. Stephenson, T. et al. A 24-month National Cohort Study examining long-term effects of COVID-19 in children and young people. Commun Med (Lond). 4(1), 255 (2024).Google Scholar 
  8. Bannister, B. A. Post-infectious disease syndrome. Postgrad Med J. 64(753), 559–567 (1988).Google Scholar 
  9. Hickie, I. et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 333(7568), 575 (2006).Google Scholar 
  10. Choutka, J., Jansari, V., Hornig, M. & Iwasaki, A. Unexplained post-acute infection syndromes. Nat Med. 28(5), 911–923 (2022).Google Scholar 
  11. Rasa, S. et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. 16(1), 268 (2018).Google Scholar 
  12. Wong, T. L. & Weitzer, D. J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 57(5), 418 (2021).Google Scholar 
  13. Lenning, O. B. et al. No signs of mast cell involvement in long-COVID: A case-control study. Scand J Immunol. 100(5), e13407 (2024).Google Scholar 
  14. de Boni, L. et al. No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache. Neurol Res Pract. 5(1), 49 (2023).Google Scholar 
  15. Kanberg, N. et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 70, 103512 (2021).Google Scholar 
  16. Havdal, L. B. et al. Neurological involvement among non-hospitalized adolescents and young adults 6 months after acute COVID-19. Front Neurol. 15, 1345787 (2024).Google Scholar 
  17. Zetterberg, H. & Blennow, K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 12(10), 563–574 (2016).Google Scholar 
  18. Kanberg, N. et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 95(12), e1754–e1759 (2020).Google Scholar 
  19. Sutter, R. et al. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Ann Neurol. 89(3), 610–616 (2021).Google Scholar 
  20. Schlepckow, K. et al. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med. 9(10), 1356–1365 (2017).Google Scholar 
  21. Fan, R. et al. TREM-1, TREM-2 and their association with disease severity in patients with COVID-19. Ann Med. 55(2), 2269558 (2023).Google Scholar 
  22. Ferri, E. et al. The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?. Front Mol Biosci. 7, 627931 (2020).Google Scholar 
  23. Di Molfetta, G. et al. Inflammation biomarkers and Alzheimer’s disease: A pilot study using NULISAseq. Alzheimers Dement (Amst). 17(1), e70079 (2025).Google Scholar 
  24. Ashton NJ, Benedet AL, Di Molfetta G, Pola I, Anastasi F, Fernández-Lebrero A, et al. Biomarker Discovery in Alzheimer’s and Neurodegenerative Diseases using Nucleic Acid-Linked Immuno-Sandwich Assay. medRxiv. 2024:2024.07.29.24311079.
  25. Feng, W. et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 14(1), 7238 (2023).Google Scholar 
  26. Team RC. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.; 2024.
  27. Gutman, E. G. et al. Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms. Mol. Psychiatry 29(10), 3106–3116 (2024).Google Scholar 
  28. Plantone, D. et al. Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases. Sci Rep. 14(1), 6429 (2024).Google Scholar 
  29. Bark, L. et al. Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19. Sci Rep. 13(1), 13144 (2023).Google Scholar 
  30. Miller, F. W. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 80, 102266 (2023).Google Scholar 
  31. Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 90(8), 870–881 (2019).Google Scholar 
  32. Giovannoni, F. & Quintana, F. J. The Role of Astrocytes in CNS Inflammation. Trends Immunol. 41(9), 805–819 (2020).Google Scholar 
  33. Charles, A. L. et al. Impaired peripheral blood mononuclear cell (PBMC) mitochondrial respiration is associated with mortality and long COVID syndrome severity in COVID-19 patients. Int J Mol Sci. 26(21), 10377 (2025).Google Scholar 
  34. Leitner, M., Pinter, D., Ropele, S. & Koini, M. Functional connectivity changes in long-Covid patients with and without cognitive impairment. Cortex 191, 74–89 (2025).Google Scholar 
  35. Kuut, T. A. et al. Efficacy of cognitive-behavioral therapy targeting severe fatigue following coronavirus disease 2019: results of a randomized controlled trial. Clin Infectious Dis : Off Public Infect Dis Soc America. 77(5), 687–695 (2023).Google Scholar 

Leave a Reply

Your email address will not be published. Required fields are marked *